Announcement

**Aaron** · 11-26-2008, 05:59 AM

Full Disclosure

Thanks Ash!

Check it out:
Special Virus Cancer Program flowchart - Google Search

Look at the bottom of this page:
aidsflowchart.htm

Look at this Full Disclosure book. This pdf is free and I actually paid almost $100 for an original copy of the book quite a while back.
http://www.energeticforum.com/health...glum-aids.html

**Aaron** · 11-26-2008, 06:15 AM

Us Patent 5676977

http://www.pat2pdf.org/patents/pat5676977.pdf
United States Patent: 5676977

United States Patent 5,676,977 Antelman October 14, 1997 Method of curing AIDS with tetrasilver tetroxide molecular crystal devices

Abstract The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function.
Inventors: Antelman; Marvin S. (Rehovot, IL) Assignee: Antelman Technologies Ltd. (Providence, RI)
Appl. No.: 08/658,955 Filed: May 31, 1996
Related U.S. Patent Documents

Application NumberFiling DatePatent NumberIssue Date

310859Sep., 1994

Current U.S. Class: 424/618 ; 514/495 Current International Class: A61K 33/38 (20060101); A61K 033/38 () Field of Search: 424/618 514/495
References Cited [Referenced By] U.S. Patent Documents

4415565 November 1983 Wysor 4915955 April 1990 Gomori 4952411 August 1990 Fox, Jr. et al. 5073382 December 1991 Antelman 5078902 January 1992 Antelman 5089275 February 1992 Antelman 5211855 May 1993 Antelman 5223149 June 1993 Antelman 5336499 August 1994 Antelman 5571520 November 1996 Antelman

Other References
"Is The AIDS Virus A Science Fiction?" by Peter H. Duesberg and Bryan J. Ellison, Policy Review, Summer 1990, pp. 40-51..
Primary Examiner: Hulina; Amy
Attorney, Agent or Firm: Salter & Michaelson

Parent Case Text

This application is a continuation-in-part of patent application Ser. No. 08/310,859 filed Sep. 22, 1994, now abandoned. Claims

What is claimed is:

1. A method of treating AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.

2. A method for increasing white blood cell counts in AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject.

3. Methods of treating AIDS-affilicted humans according to claims 1-2 where the concentration of said molecular crystals is approximately 40 PPM of the total blood weight of the human subject. Description

BACKGROUND OF THE INVENTION

The present invention relates to the employment of molecular crystals as anti-AIDS devices, but more particularly to the molecular crystal semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which has two monovalent and two trivalent silver ions per molecule, and which through this structural configuration enables intermolecular electron transfer capable of killing viruses and binding them to the resulting silver entity so that a single intravenous injection will completely obliterate acquired immune deficiency syndrome (AIDS) in humans. Furthermore, said devices are capable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or not created by the AIDS virus (HIV); so as to restore the immune system.

The present invention is based on concepts previously elucidated in applicant's U.S. Pat. No. 5,336,499 which discloses the destruction and inhibition of bacteria, algae and the AIDS virus in nutrient life supporting systems by using said silver oxide devices. Example 3 of said patent discloses that 18 PPM of said crystal devices could totally suppress the AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned patent, further testing revealed complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the fact that said devices were harmless when ingested and inhaled, being non-toxic.

Encouraged by these evaluations and successes, applicant obtained permission to evaluate the crystals in vitro against murine acquired immune deficiency syndrome (MAIDS). Only one facility in the State of Israel is licensed for these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is affiliated with the Hebrew University-Hadassah Medical School where said evaluations were done.

The initial evaluations entailed experimenting with various silver moieties cited in applicant's aforementioned patent, concentrations, non-reactive buffers and modes of administration. After about 18 months of judicious efforts and initial failures, success was finally achieved in destroying the MAIDS virus in C57BL mice with a single intravenous injection. The results of this test program comprise Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the inventor was able to test the efficacy of said devices on two select etiological groups of terminal AIDS patients in a clinic in Tegucigalpa, Honduras, Central America.

The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Current indicator diseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categories with the approximate percent distribution among AIDS patients:

______________________________________ 1. P. carinii pneumonia 51% 2. Wasting syndrome 19% 3. Candidiasis 13% 4. Kaposi's sarcoma 11% 5. Dementia 6% ______________________________________

This invention concerns itself with the treatment and cure of candidiasis and wasting syndrome AIDS patients with Tetrasil*. These two groups account for approximately one third of AIDS cases.

Stedman's Medical Dictionary (Williams & Wilken's 26th Ed., 1995) defines wasting syndrome "as a condition of 10% weight loss in conjunction with diarrhea or fever . . . Associated with AIDS (p. 1744)."

OBJECTS OF THE INVENTION

The main object of the invention is to provide for a molecular scale device of a single tetrasilver tetroxide crystalline molecule capable of restoring the immunity of AIDS afflicted humans of the two AIDS etiological subgroups, candidiasis and wasting syndrome.

Another object of the invention is to provide for immunity restoration in said AIDS afflicted humans through a single injection.

Another object of this invention is to destroy ISM in humans manifesting AIDS diseases of said AIDS etiological subgroups irrespective as to whether said ISM was HIV induced, since it is known that humans may manifest AIDS and still be HIV negative, and thus restore the immune system in said humans.

Another object of this invention is to destroy the AIDS virus when present in the systems of said AIDS afflicted humans.

**Aaron** · 11-26-2008, 06:15 AM

US PATENT 5676977 part2

SUMMARY OF THE INVENTION

This invention relates to a molecular scale device not only capable of destroying the AIDS virus, but of purging the human bloodstream of pathogens and restoring immunity to AIDS patients of the candidiasis and wasting syndrome categories. Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag.sub.4 O.sub.4). The crystal lattice of this molecule has a unique structure since it is a diamagnetic semiconducting crystal containing two mono and two trivalent silver ions, which in effect are capable of "firing" electrons under certain conditions which will destroy AIDS viruses, other pathogens and immune suppressing moieties (ISM), not only through the electrocution mode, but also by a binding process which occurs simultaneously with electron firing, namely, binding and chelation of divalent silver, i.e., the resulting product of the electron transfer redox that occur when the monovalent silver ions are oxidized and the trivalent ions are reduced in the crystal. The binding/chelation effect occurs at active sites of the AIDS virus, pathogens and ISM. Because of the extremely minute size of a single molecule of this crystal, several million of these devices may be employed in concert to destroy a virus colony to purge a life support system of ISM and pathogens with the consumption of only parts per trillion of the crystal devices. Thus an optimum of 40 PPM of the devices by weight of human blood was found to be sufficient to completely obliterate AIDS. This concentration is slightly over double of the optimum concentration recommended in applicant's aforementioned U.S. patent for the destruction of the human AIDS virus in vitro. Other details concerning the structure of the crystal and its mechanism against pathogens, the AIDS virus and ISM would analogously hold here, and have already been further elucidated in said patent.

The actual destruction of pathogens, ISM and the AIDS virus is effectuated by injection of a suspension of these devices in distilled or deionized water with a non-reacting electrolyte directly, i.e. intravenously, into the bloodstream. A single injection is all that is required under these conditions. Accordingly, humans injected in this manner, upon being inspected after three weeks or more had elapsed and compared with similar humans that had been given placebos, were completely cured of AIDS. The control group still manifested AIDS. Accordingly, the tetrasilver tetroxide device performed in concert with and in full conformity with the ultimate objects of this invention. Furthermore, three out of four wasting syndrome terminal patients and four out of the five candidiasis terminal patients were still alive in 1995 after a year and a half had elapsed from their initial injection. By that time all the AIDS patients had been released from the clinic and allowed to return home.

Other objects and features of the present invention shall become apparent to those skilled in the art when the present invention is considered in view of the accompanying examples. It should, of course, be recognized that the accompanying examples illustrate preferred embodiments of the present invention and are not intended as a means of defining the limits and scope of the present invention.

EXAMPLE 1

Five patients afflicted with AIDS of the candidiasis etiological category were segregated for Tetrasil treatment. The rationale for selecting them was based on facts presented in an article by Peter H. Duesberg and Brian J. Ellison entitled "Is The AIDS Virus A Science Fiction?" (Policy Review, Summer 1990 pp. 40-51). Only the factual presentations of the article were utilized and the hypothesis of the authors was ignored. The facts presented in the article related to the method of selecting AIDS patients based on the five aforementioned etiological subgroups targeted by the CDC, and the evidence presented, that there is AIDS without HIV as well as with it so that an anti-viral agent in most instances will not necessarily restore the immunity system.

Evaluations with Tetrasil were conducted on AIDS patients at Lucha Contra el Sida, Comayaguela, Honduras. The patients two weeks prior to inoculation were removed from their AZT, AIDS therapy. Tetrasil was administered at approximately 40 PPM of blood volume per patient as a suspension in a proprietary buffer solution (pH=6.5), supplied by Holipharm Corporation.

The results of evaluations with candidiasis are tabulated in Table I under its disease category. All patients evaluated were terminal. Some, however, were in moderate (m) condition and others in poor (p) as designated in the Table. The I and F designations refer to initial and final values as shown. WBC indicates white cell blood count. The H column, following CD 8, indicates whether hepatomegaly occurred. This was an unfortunate consequence of the treatment which resulted in enlarged livers in all patients except the second one. Despite hepatomegaly, there was no interference with liver function.

The onset of hepatomegaly was not spontaneous and varied from patient to patient, being in the range of 4-16 days.

It should also be noted that shortly after injection of Tetrasil there were indications of fever (symbolized by T in the Ag.sub.4 O.sub.4 column), sometimes accompanied by fatigue (F). The body temperature was invariably 38.5.degree. C. (101.3.degree. F.). This was indicative of restoration of the immune response of the body, since normally the body will destroy pathogens when the immune system is functional by raising the temperature. The patient who died; first responded favorably to Diflucan, which previously gave no response. He was cured of his candidiasis, but unfortunately succumbed to his previous body damage. All the other candidiasis syndrome people who previously did not respond to the indicated medications subsequently responded after the Tetrasil treatment. Further evidence of the recovery of the AIDS patients manifested itself 30 days after the initial injection when white blood cell counts were taken. They are shown in Table I under the WBC column, which gives the initial and final WBC. All candidiasis patients showed a dramatic increase in their white blood cell counts, indicative of the restoration of their immunity systems.

EXAMPLE 2

The above protocol of Example 1 was repeated with AIDS patients exhibiting wasting syndrome. The results of their treatment are tabulated in Table I under the disease category of said syndrome. It should be noted that two of the four wasting syndrome patients showed improved white blood counts. The female patient, whose condition improved from poor and terminal to be among the living, showed a decrease in the WBC. However, she showed an increase in body temperature which was indicative of immune response. The test results indicate that one cannot rely on a single factor to indicate the demise of AIDS. The usual HIV marker CD 4 initial and final are irrelevant. ISM suppression appears to be more critical than the destruction of HIV. AIDS was suppressed, any permanent damage that had been done to the patients in the course of their succumbing to AIDS was not obviously cured or corrected by said crystal device treatment, rather said injury persisted and the patient was improved with respect to AIDS but still suffered from said permanent injury or impairment previously inflicted.

TABLE I __________________________________________________ ________________________ Response of AIDS Patients to Single 40 PPM Ag.sub.4 O.sub.4 Inoculation Date Weight DISEASE PATIENT Inoc. WBC CD 4 DEATH Lbs. Group Sex Age Medictn 1994 I F I F CD 8 H 1944 I F Ag.sub.4 O.sub.4 __________________________________________________ ________________________ Candidiasis M p 28 Diflucan 5/5 1,200 4,200 41 -- 221 + 6/11 82 76 T F m 33 " 5/5 6,000 6,700 554 872 394 - 98 98 T F m 33 Ketaconzl 5/27 2,600 3,850 248 181 951 + 123 123 T M p 62 " 6/2 3,300 3,700 89 237 59 + 105 92 F F m 31 Pentamidn 6/2 2,400 3,050 9 181 65 + 121 118 Pain Wasting M m 27 5/27 3,600 4,600 39 14 709 + 119 120 T Syndrome M m 28 5/27 2,750 -- 10 -- 60 + 7/19 121 119 T, F F p 43 5/27 3,600 2,700 68 246 248 + 101 98 T, F M m 19 5/10 3,850 5,400 137 36 48 + 103 106 T, F __________________________________________________ ________________________

As this invention may be embodied in several forms without departing from the spirit or essential characteristics thereof, the present embodiments are therefore illustrative and not restrictive, since the scope of the invention is defined by the appended claims rather than by the description preceding them, and all changes that fall within the metes and bounds of the claims or that form their functional as well as conjointly cooperative equivalents, are therefore intended to be embraced by these claims.

**Aaron** · 11-26-2008, 06:24 AM

Youtube Interview

YouTube - Armstrong Williams interview with Dr. Boyd Graves

As the skeptical doctor admits..."I've read none". Typical.

**Aaron** · 11-26-2008, 06:44 AM

compound comments??

Any comments on this?

"The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electrons capable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function."

**Genie** · 11-26-2008, 04:47 PM

Thank you for posting this information. I find quality silver products to be extermely effective in curing infections and illness as a topical or sublingual, and now to find out that someone has actually found a way to inject a molecular version that can maintain 40PPM in human blood is truly amazing!

In reviewing the information above, one thing really stands out to me:

"A single injection is all that is required under these conditions. Accordingly, humans injected in this manner, upon being inspected after three weeks or more had elapsed and compared with similar humans that had been given placebos, were completely cured of AIDS. The control group still manifested AIDS. Accordingly, the tetrasilver tetroxide device performed in concert with and in full conformity with the ultimate objects of this invention. Furthermore, three out of four wasting syndrome terminal patients and four out of the five candidiasis terminal patients were still alive in 1995 after a year and a half had elapsed from their initial injection. By that time all the AIDS patients had been released from the clinic and allowed to return home."

How wonderful that these people were able to get their lives back. And how wonderful it would have been (and can be for others) when using this treatment at an earlier stage, before certain permanent damage is done due to the immune disease.

I will keep reading and looking at the links provided to get even more info and I will certainly be doing what I can to support this important invention!!!

Thank you very much again for posting.

**ashtweth** · 11-29-2008, 01:25 AM

Aaron , thanks allot for those links man, i am taking all the links you posted to my doctor who works with AIDS patients, so man you cannot know how much i appreciate you finding all those dood. Why doesn't the gay community know about this?

Thanks
Aaron.

Ash

**Bob Smith** · 11-29-2008, 02:52 AM

AIDS Destroyed by Blood Electrification

Check out "blood electrification" and "zapper." Bob Beck was the first, I believe, to develop a hand held blood electrification unit, which he claimed killed the AIDS virus by sending a microcurrent through the wrist into the radial and ulnar arteries. Beck claimed that persons using his system could go from HIV+ to negative in 3 weeks' time. A simple unit can be built for less than $20 US. Beck's schematics are on Educate-Yourself.org:The Freedom of Knowledge; The Power of Thought.
B

**Bob Smith** · 11-29-2008, 02:58 AM

Here's a page with some links to Beck's schematics - there are others on the 'net as well:
Blood Electrification & Cured AIDS Testimonials (Nov 12, 2008)

**Aaron** · 11-29-2008, 03:56 AM

Full Disclosure

Ash,

I've known about the Full Disclosure book for about 10 years. It was by pure synchronicity when I saw that in it was the reference towards a natural chemical solution (not the silver). Deoxyribonucleosides/tides.

One day I was driving listening to a lecture about cordyceps for a formula I was working on and found out that there are some cordyceps grown in a low oxygen low temperature environment indoors that makes 500%+ more concentrations of certain sugars like Ribose...but in a low oxygen environment, for it to conserve oxygen, it makes a deoxygenated ribose molecule.

When it is lacking an oxygen, it is part of a complete deoxyribose type compounds...part of DNA.

If it is oxygenated, then it is a riboside like what makes up RNA and viruses.

AZT and other compounds for aids patients are made of ribosides...might temporarily make symptoms look like they're being suppressed, while the ribosides are JUNK FOR FOR VIRUSES....and makes sure the virus has what it needs to survive in a very strong way.

In Full Disclosure, it talks about someone being killed over in Ghana who had a successful aids cure using the native herbs of the area I believe. He was killed and all his material was taken.

I found a source of cordyceps hybrid that was super loaded with the deoxygenated compounds in it. One person there asked contacts in Ghana carrying out a SUCCESSFUL study on aids patients using this cordyceps and found that the story in that book not only happened but people are still talking about it to this very day. People were crushed by this because they saw that man as their only hope.

Thankfully, there are other things that work. All of this is coming out faster and faster.

**Aaron** · 11-29-2008, 03:58 AM

Tetrasil - Imusil - about the silver compound

IMUSIL

Donation of Imusil

Dr Marvin S Antelman, the inventor of a treatment for HIV/AIDS, has generously donated six single injections of Imusil for Compassion Response Network AIDS trials. Three of these injections have been sent to the Harare project and await funding for treatment of three HIV/AIDS patients, and three injections have been sent to Kinshasa where three HIV/AIDS patients have been treated in an Imusil trial conducted during the year 2004. One injection is all that is needed.

Imusil is a product of Marantech Holdings LLC, Providence, Rhode Island, USA. For information, contact them at info@marantech.com. You are also invited to look up the Marantech website at http://www.Marantech.com

What is Imusil?

Marantech has identified and patented use of a number of Electron Jumping Compounds (EJCs) that have been found in independent laboratory testing to exhibit powerful antimicrobial activity. However, to date the bulk of Marantech�s testing of EJCs for pharmacological safety and efficacy has centered on tetrasilver tetroxide (abbreviated TST, a multivalent metallic oxide uniquely structured as a semi-conducting molecular crystal device. Independent laboratory and clinical testing indicates that TST molecules selectively target and kill rapidly proliferating organisms (e.g., viruses, bacteria, fungi and protozoa) through a multitude of nano-level electrical discharges followed by physical combination (chelation) and release of singlet oxygen at the pathogenic site. Normal tissues are generally unaffected. The unusual suspected kill method may thwart the development of pathogens resistant to Tetrasil therapy.

Antimicrobial Activity: It has been known for several years that TST is a potent antimicrobial agent that kills a broad spectrum of viruses, fungi, algae and bacteria (including drug resistant strains) in-vitro at concentrations that have been certified safe by the EPA for usage in swimming pools ("EPA Levels"). Clinical studies commissioned by Marantech and conducted by Exetec Labs in Honduras, indicate that topically applied TST can lead to dramatic and rapid improvements in such infection-caused skin conditions as cold sores, herpes lesions, shingles, follicultis, diabetic ulcers, bedsores, tinea versicolor, and ringworm. In topical form, TST is formulated as Tetrasil and is available through their website, Home: Aidance Skincare All-Natural Products with Electron-Active� Silver Oxide . Moreover, building on earlier informal testing against systemic infections (including Candida albicans, dysentery and AIDS), Exetec was commissioned to conduct clinical studies of TST as an intravenous treatment for AIDS (Imusil).

Oncological Activity: Independent in-vitro lab testing also found that TST is lethal to a dozen common forms of human cancer cells. Marantech therefore expanded the Exetec clinical studies to include topical treatment of skin tumors. Reported results include healing of skin lesions and apparent elimination of atypical cells in many patients with neurofibromatosis and early-stage malignant melanomas, basal cell and squamous cell carcinomas.

Other Dermatological Activity: Exetec also reported that topically applied TST (formulated as Tetrasil) appears to promote healing of skin conditions that are neither cancerous nor infected, including atopic dermatitis (eczema) , psoriasis, and third-degree burns, apparently by triggering an increase in the production of new, healthy tissue.

Dr Antelman's Theory on AIDS

"Our approach to AIDS is non-conventional. There is HIV without AIDS and AIDS without HIV. Nobel Prize winner Kary Mullis has pointed this out as well as his position that AZT is a failure. Accordingly we have patients who display viral load reduction and those that do not who are nevertheless cured of AIDS because in certain cases HIV will be neutralised and remain in the body with no visible change as far as the present "viral load" test technology allows for."

Dr Antelman indicated that there exist 5 standard etiologies (reasons of causation) for AIDS:

p.carinii pneumonia
Wasting Syndrome
Candidiasis
Kaposi�s sarcoma
Dementia

"My own recent observations are that irrespective of the etiology, certain AIDS patients have EBV causing them to have chronic fatigue syndrome. When they are cured they will not show viral load differences because EBV is latent or active."

"Those patients that display the same viral load show differences in their white blood cell count and if not in weight gain when they have wasting syndrome. Apparently, the current diagnostic methods science relies on are not adequate to show a marker for certain AIDS patients who have recovered leading normal lives. "

Treatment of AIDS
From an article, Antiviral Tetrasilver Tetroxide Therapy, by Dr Marvin S Antelman. The full 5-page article is available through Dr Antelman or Compassion Response Network.

AIDS-Non Terminal Patients: "Clinical testing was performed at Exetec Lab, SA in Honduras under the supervision of Dr. L Roland Valenzuela. Thirty patients were selected from three etiological AIDS groups, 10 for each group namely, Candidiasis, Wasting Syndrome and p. carinii pneumonia. Each patient was given an intravenous infusion of Imusil administered over a three hour period. All patients experienced temperature elevation within 48 hours of administering the Imusil, which was indicative that the immune system was now functioning along with the fact that all patients also started to have dramatic increases in their white blood cell counts. At the end of 30 days of observation, all patients were cured of AIDS. All patients presenting Wasting Syndrome were completely cured of the Syndrome; the average patient gaining approximately one half pound per day. Three patients were completely cured of their pneumonia. Because the protocol was changed from direct injection to slow i.v. infusion of the Imusil, there were no side effects of hepatomegaly."

Imusil�, Tetrasil� and Electron-Jumping Compounds� are registered trademarks of Marantech Holding LLC. Protected by several US and international patents, and additional patents pending.

**Aaron** · 11-29-2008, 04:03 AM

Tetrasil product

Look like this silver product is only being marketed in skin products:
Home: Aidance Skincare All-Natural Products with Electron-Active� Silver Oxide

Unfortunate if this is the only application people can get their hands on.

**chasson321** · 03-02-2009, 12:14 AM

MMS and Aids

last edit......

Announcement

Boyd Graves -AIDS Cure!

Boyd Graves -AIDS Cure!

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment